AI assistant
AstraZeneca PLC — M&A Activity 2018
Dec 6, 2018
5229_rns_2018-12-06_99177d25-1f8d-42a9-ba2c-9d2ae56d0d6b.html
M&A Activity
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 5771J
AstraZeneca PLC
06 December 2018
6 December 2018 07:00 GMT
Divestment of rights to Alvesco, Omnaris
and Zetonna to Covis Pharma completed
AstraZeneca has completed an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines. The transaction does not include the transfer of any AstraZeneca employees or facilities.
Under the terms of the agreement, AstraZeneca has received a payment of $350m from Covis Pharma. As AstraZeneca will not maintain a significant ongoing interest in the medicines, the upfront payment, net of a significant, non-cash derecognition of an intangible asset will be reported as Other Operating Income & Expense in the Company's financial statements in the fourth quarter of 2018. The agreement does not affect the Company's financial guidance for 2018.
About Covis Pharma
Covis Pharma is headquartered in Zug, Switzerland and is a global speciality pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Additional information is available at www.covispharma.com.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
| Media Relations | ||||
| Karen Birmingham | UK/Global | +44 203 749 5634 | ||
| Rob Skelding | UK/Global | +44 203 749 5821 | ||
| Matt Kent | UK/Global | +44 203 749 5906 | ||
| Gonzalo Viña | UK/Global | +44 203 749 5916 | ||
| Jennifer Hursit | UK/Global | +44 203 749 5762 | ||
| Jacob Lund | Sweden | +46 8 553 260 20 | ||
| Michele Meixell | US | +1 302 885 2677 | ||
| Investor Relations | ||||
| Thomas Kudsk Larsen | +44 203 749 5712 | |||
| Henry Wheeler | Oncology | +44 203 749 5797 | ||
| Christer Gruvris | Cardiovascular; Metabolism | +44 203 749 5711 | ||
| Nick Stone | Respiratory; Renal | +44 203 749 5716 | ||
| Josie Afolabi | Other | +44 203 749 5631 | ||
| Craig Marks | Finance; Fixed Income | +44 7881 615 764 | ||
| Jennifer Kretzmann | Retail Investors | +44 203 749 5824 | ||
| US toll-free | +1 866 381 7277 | |||
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
MSCLLFSEFELEIIT